1.Application of Medication Therapy Management Combined with Medicine Gene Detection in Individualized Pharmaceutical Care of An Elderly Patient with Warfarin-induced Acute Upper Gastrointestinal Hemorrhage
Lan WANG ; Qiantai MAO ; Xiaoning ZHANG ; Zhaoshuai JI ; Chao AI
China Pharmacy 2019;30(17):2388-2393
OBJECTIVE: To investigate how pharmacists provide through individualized pharmaceutical care for patients medication therapy management(MTM) combined with medicine gene detection, and to promote rational drug use in clinic.METHODS: A case of elderly comorbidity with acute upper gastrointestinal hemorrhage caused by Warfarin sodium tablets was taken as an example. The patient had a history of type 2 diabetes mellitus and hypertension. Coronary artery bypass grafting was performed two months before admission, and urinary tract infection occurred half a month ago. Medication therapy course was analyzed retrospectively before and after hospitalization; based on gene typing detection of CYP2C9*3 and VKORC1-1639, the individualized dose of Warfarin sodium tablets was evaluated. MTM was perfomed for acute upper gastrointestinal hemorrhage and all medication of patient to formulate individualized medication scheme. RESULTS: The genotyping of warfarin CYP2C9*3 and VKORC1-1639 indicated that the patients were of super slow metabolic type. The recommended dosage of warfarin should be 0.86-1.86 mg/d. Based on MTM analysis of acute upper gastrointestinal hemorrhage, the main causes of acute upper gastrointestinal hemorrhage were Warfarin sodium tablets 3.0 mg/d, poor drug compliance, disease status and co-morbidity and multi-drug combination. Clinical gastrointestinal hemorrhage of the patients were improved after drug withdrawal, anticoagulant drugs was changed into Rivaroxaban tablet,10 mg/d. Through MTM for all drug use in the patient, results of medication reorganization showed that Diltiazem hydrochloride tablet, Amoxicillin/clavulanate potassium dispersible tablet, Compound vitamin tablet were stopped; hypoglycemic drug Glimepiride tablet was changed into Gliquidone tablet; Metoprolol tartrate tablet was changed into Bisoprolol tablet after coronary artery bypass graft; proton pump inhibitor Esomeprazole enteric-coated tablet was changed into Pantoprazole sodium enteric-coated capsule. CONCLUSIONS: The pharmaceutical care mode of MTM combined with medicine gene detection can guide rational drug use in clinic, realize individualized pharmaceutical care, improve patient compliance and prevent problems related to adverse drug reactions.
2.Development and application of drug-induced liver injury surveillance and assessment system
Chao AI ; Zhaoshuai JI ; Yaxin ZHANG ; An LIU ; Xuesi ZHOU ; Zhonghao CHEN ; Ji WU
China Pharmacy 2023;34(19):2409-2413
OBJECTIVE To establish the drug-induced liver injury (DILI) surveillance and assessment system (DILI-SAS), and to improve the diagnostic efficiency of clinical DILI. METHODS The DILI-SAS was constructed by using natural language processing technology to mine and utilize all inpatient medical record data, and combined with Roussel Uclaf causality assessment method (RUCAM). The medical records of 19 445 hospitalized patients from August 2022 to January 2023 were detected to verify the performance of the system and manually analyze the basic data of patients with DILI and the distribution of the first suspected drugs. RESULTS The overall accuracy rate of the DILI-SAS system was 91.95%, and the recall rate was 93.20%. Seventy-five DILI cases were detected, and the DILI incidence rate was 385.70/100 000 people. The efficiency of DILI monitoring by human- computer coupling was increased by about 60 times of manual monitoring; males (61.33%) and patients over 60 years old (56.00%) were the most common in the 75 cases of DILI. The clinical type of liver injury was hepatocyte injury (69.33%), the incubation period was mainly 5-90 days after treatment (62.67%), and the RUCAM score between 3 and 5 was the most common (66.67%); pharmacological distribution of the first suspected drugs was mainly dihydropyridines, HMG CoA reductase inhibitors, proton pump inhibitors, etc. The specific drugs were atorvastatin, omeprazole, ceftriaxone, metronidazole and other drugs. CONCLUSIONS The establishment of DILI-SAS can improve the evaluation efficiency on the basis of ensuring the accuracy degree, and provide a solution for the early identification, diagnosis and evaluation of clinical DILI.